Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma
Recruitment status was Active, not recruiting
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment.
PURPOSE: This research trial studies biomarker expression in tissue samples from young patients with anaplastic large cell lymphoma.
Genetic: microarray analysis
Genetic: protein expression analysis
Genetic: western blotting
Other: flow cytometry
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: mass spectrometry
|Official Title:||Expression of T Immunoregulatory Proteins in ALK+ Anaplastic Large Cell Lymphoma (ALCL)|
- Expression of immunoregulatory proteins including CD4, FOXP3 and CD276 in ALCL [ Designated as safety issue: No ]
- Correlation of CD4, FOXP3, and CD276 with ALK autoantibody response in patients enrolled in ANHL0131 [ Designated as safety issue: No ]
|Study Start Date:||May 2011|
|Estimated Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
- To determine the expression of immunoregulatory proteins including CD4, FOXP3 and CD276 in anaplastic large cell lymphoma (ALCL).
- To correlate the expression of these proteins with the levels of anaplastic lymphoma kinase (ALK) autoantibodies in patient of ANHL0131.
OUTLINE: Archived tissue microarray samples are analyzed by mass spectrometry and validated by Western blotting, flow cytometry, and IHC.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01366170
|Principal Investigator:||Megan S. Lim, MD, PhD||C.S. Mott Children's Hospital at University of Michigan Medical Center|